William G. Wierda

Hematology | Oncology

1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 411 publications

The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemia.

The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemia.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: May 06, 2026

Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.

Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 20, 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 13, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Journal: Blood

Published: February 05, 2026

Developing MRD as an early endpoint for accelerated approval in CLL.

Developing MRD as an early endpoint for accelerated approval in CLL.

Journal: Seminars in hematology

Published: February 01, 2026

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.

Journal: Current medical research and opinion

Published: January 30, 2026

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

The Care and Cure of the Leukemias in 2026.

The Care and Cure of the Leukemias in 2026.

Journal: American journal of hematology

Published: December 03, 2025

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

Journal: American journal of hematology

Published: November 25, 2025

Showing 1-12 of 411

Last Updated: 09/26/2026